Speech Processing in Stuttering

This research is being done to better understand stuttering, specifically how people who stutter may process and/or produce speech. Eligible participants enrolled will complete a variety of computer and speech-based tasks on up to 2 visits.

Study Overview

• Status: Recruiting
• Conditions: Stuttering; Stuttering, Childhood; Stuttering, Adult
• Intervention / Treatment: Behavioral: Speech and non-speech tasks

Detailed Description

The study team will update the record to include the secondary identification number once the NIH has released the funds.

• Study Type: Interventional
• Enrollment (Estimated): 140
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Emily Garnett, PhD; Phone Number: 734-232-3371; Email: emilyog@umich.edu

Study Locations

• United States
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Recruiting
      • University of Michigan
      • Contact: Emily Garnett, PhD; Phone Number: 734-232-3371; Email: emilyog@umich.edu
    • East Lansing, Michigan, United States, 48824
      • Recruiting
      • Michigan State University
      • Contact: Devin McAuley, PhD; Phone Number: 517-353-9069
      • Principal Investigator: Devin McAuley, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria (adults who do not stutter):

• 18-65 years old
• English as primary language
• Normal speech, language, hearing, cognition

Exclusion criteria: (adults who do not stutter)

• Personal or family history of stuttering
• Major medical or psychiatric illness

Inclusion criteria: (adults who stutter)

• Aged 18-65 years
• English as primary language
• Normal speech, language, hearing, cognition (other than stuttering)
• Currently stutters

Exclusion criteria: (adults who stutter)

• Speech therapy within the past year
• Major medical or psychiatric illness

Inclusion criteria: (children who do not stutter)

• Aged 6 to 17 years
• English as primary language
• Normal speech, language, hearing, cognition

Exclusion criteria: (children who do not stutter)

• Personal or family history of stuttering
• Major medical or psychiatric illness
• Language/motor delay

Inclusion criteria: (children who stutter)

• Aged 6 to 17 years
• English as primary language
• Normal speech, language, hearing, cognition (other than stuttering)
• Currently stutters

Exclusion criteria: (children who stutter)

• Major medical or psychiatric illness
• Language/motor delay

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Adults who stutter (AWS); Participants will have 2 visits.	Behavioral: Speech and non-speech tasks; Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
Other: Healthy Adults; Participants will have 2 visits.	Behavioral: Speech and non-speech tasks; Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
Experimental: Children who Stutter; Participants will have 1 visit.	Behavioral: Speech and non-speech tasks; Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
Other: Healthy Children; Participants will have 1 visit.	Behavioral: Speech and non-speech tasks; Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase locking value (PLV) - Session 1 speech tasks	The degree of synchronization will be measured by computing the PLV between subject's produced speech and the heard speech. The PLV is a vector with a value between 0 and 1 that reflects the phase difference between two signals.	Session 1 (up to 4 hours)
Phase locking value (PLV) - Session 2 speech tasks	The degree of synchronization will be measured by computing the PLV between subject's produced speech and the heard speech. The PLV is a vector with a value between 0 and 1 that reflects the phase difference between two signals. Session 2 is for adults only.	Session 2 (up to 4 hours)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase locking value (PLV) - Non-speech tasks	The degree of synchronization will be measured by computing the PLV between subject's produced response and the auditorily presented stimuli. The PLV is a vector with a value between 0 and 1 that reflects the phase difference between two signals.	Session 1 (up to 4 hours)

Collaborators and Investigators

• Sponsor: University of Michigan
• Collaborators: National Institute on Deafness and Other Communication Disorders (NIDCD)
• Investigators: Principal Investigator: Emily Garnett, PhD, University of Michigan

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2022
• Primary Completion (Estimated): May 1, 2024
• Study Completion (Estimated): May 1, 2024

Study Registration Dates

• First Submitted: June 10, 2021
• First Submitted That Met QC Criteria: June 10, 2021
• First Posted (Actual): June 18, 2021

Study Record Updates

• Last Update Posted (Actual): September 22, 2023
• Last Update Submitted That Met QC Criteria: September 21, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Healthy Adults; Healthy children
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Language Disorders; Communication Disorders; Speech Disorders; Stuttering
• Other Study ID Numbers: HUM00194953; 1R21DC019429-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No